Nimbus Synergies Leads $20 Million Strategic Investment in Clarius Mobile Health to Accelerate Growth

Nimbus Synergies, investor, partner, and mentor to Canada’s leading health technology companies, is pleased to announce the completion of a $20 million strategic investment in Clarius Mobile Health. This new investment was led by Nimbus Synergies and Export Development Canada to enable Clarius to expand its commercial scale and capitalize on the momentum created by the introduction of the company’s third-generation product line earlier this year. New investor, Nicola Wealth, as well as existing investors, BMO Capital Partners and Pender Ventures, also participated in the round.

Clarius Mobile Health is a leading provider of high-definition wireless ultrasound systems. Clarius wireless scanners are used in hospitals, private practices, and veterinary clinics around the world. Designed for all medical specialists, the new third-generation pocket-sized scanners are 30% lighter and smaller and available in the United States with compelling pricing and new features.

Point-of-care ultrasound (“POCUS”) is the new stethoscope and Clarius’ exceptional performance in 2021, which delivered 100% revenue growth year-over-year, and increasing focus on artificial intelligence and Software-as-a-Service (SaaS) to deliver an uncompromising handheld ultrasound solution, underscores the market opportunity for a leader in this industry. Furthermore, the company’s recently launched SaaS model is gaining strong adoption with users highlighting the company’s ability to leverage its hardware and software expertise for an integrated, intuitive, and exceptional customer experience.

“Today, Clarius is the most disruptive ultrasound platform company in the market”, said Paul Geyer, CEO of Nimbus Synergies. “Fusing high performance ultrasound imaging, cloud data and artificial intelligence in a powerful ecosystem that provides significant clinical value to improve patient care. The company has been extremely capital efficient to date, and we know these additional funds will fuel even faster growth.”

Geyer, who will be joining the company’s Board, is a successful medtech entrepreneur, investor, experienced Board member, and venture capitalist. Over the past 25 years, he has founded or led three companies through their growth phases, two of which have become anchor medical device companies in the Vancouver, BC area, employing more than 350 people.

“We are very pleased to welcome Nimbus Synergies to our syndicate and to continue working with such a committed group of investors,” commented Maria Pacella, Managing Partner of Pender Ventures. "We are also enthused to leverage Paul’s knowledge and expertise as part of our Board moving forward.”

“Paul is a recognized leader both in the medical technology sector as a successful serial entrepreneur as well as in the broader innovation and early-stage investment ecosystem as an investor,” explained Clarius’ President, Ohad Arazi. “Paul has served on numerous Boards, is one of the most active and respected medtech investors in British Columbia, and, with Nimbus Synergies, is a welcomed partner in venture capital,” continued Arazi.

ABOUT NIMBUS SYNERGIES

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the health technology sector through its leadership as investor, partner, and mentor.

 

Follow Nimbus Synergies on LinkedIn (https://www.linkedin.com/company/nimbus-synergies) and Twitter @nimbussynergies

 

ABOUT CLARIUS MOBILE HEALTH

Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care. Today, Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost.

Nearly two million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide.

Learn more at www.clarius.com.

Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization

Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors.

The strategic equity round, which was oversubscribed by 150%, comes after the launch of VelacurTM, the first handheld 3D liver health assessment solution, in the US market in early 2021.

Cleared by the FDA, VelacurTM is a handheld, point of care ultrasound solution that quantifies liver disease using technology similar to MRI elastography combined with 3D tissue sampling. It provides consistently accurate results, enabling a clear picture of liver health in real time, so physicians can be confident in the diagnosis, treatment and care of their patients with chronic liver disease. Unlike biopsy and MRI, the procedure is non-invasive, comfortable and convenient. It takes about five minutes and can be performed in a physician’s office.

“Velacur is poised to make a mark as an innovative solution to detect liver disease, and we’re excited to have the support of investors who believe in our vision and mission,” states George Aliphtiras, CEO of Sonic Incytes. “Their support is based on the recognition that fatty liver disease is a significant health issue and underscores the need for an accurate, accessible and affordable point of care diagnostic tool to assess and manage millions affected by this often-silent disease.”

In addition to Nimbus Synergies’ investment, Paul Geyer, CEO of Nimbus Synergies, will be joining the Sonic Incytes’ Board of Directors effective immediately. Over the past 30 years, Geyer has founded or led three companies, and since 2008 has focused on assisting entrepreneurs in building successful businesses as a mentor, partner, and investor.

“Paul is a successful entrepreneur, board member, angel investor, and venture capitalist, and we’re pleased to leverage his expertise as part of our Board of Directors,” explains Aliphtiras.

 “Fatty liver disease is a growing global epidemic affecting more than one billion people and is commonly associated with diabetes and obesity. This disease causes permanent liver damage and mortality,” states Geyer. “Our vision at Nimbus is to improve health through Canadian-led innovation and by investing in this technology spun-out of the University of British Columbia, we are helping solve real-world health crises like chronic liver disease.”

 About Sonic Incytes Medical Corp.
Sonic Incytes believes in creating accessible and affordable diagnostic solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes has made it its mission to reduce the disease by enabling routine assessment and improved management of liver health. Its breakthrough, point of care ultrasound solution, VelacurTM, is redefining the standard of care in quantifying chronic liver disease – with diagnostic accuracy comparable to MRI.

Founded in 2017, Sonic Incytes is a health technology company headquartered in Vancouver, British Columbia, Canada. Follow us on Twitter, LinkedIn, YouTube and www.sonicincytes.com.

About Nimbus Synergies
Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the digital health sector through its leadership as investor, partner, and mentor.

Follow Nimbus Synergies on LinkedInor visit www.nimbusinc.vc to learn more.